Galaxy Therapeutics Submits Final Module of PMA to U.S. FDA for SEAL™ Device in Wide-Neck Bifurcation Aneurysms

MILPITAS, Calif., April 27, 2026 /PRNewswire/ -- Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, today announced the submission of its final module of its Premarket Approval (PMA) application to the U.S. Food and Drug...